Please read newsletter reader Lili Eylon’s personal account of Alpha DaRT radiation cancer therapy developed by Israel’s Alpha Tau (see here previously). Lili was one of 56 patients in DaRT’s human study at Hadassah Medical Center – its second skin … Continue reading →

Israel’s Imagene AI develops fast AI-based cancer diagnostics to help identify personalized treatment. Using a digitized biopsy image, Imagene delivers real-time precision-based molecular analysis, increased accuracy and reducing the time required for results, from several weeks to just two minutes. … Continue reading →

Israel’s Genoox (see here previously) has developed Franklin – a repository of genetic biopsy information relating to cancer mutations. Doctors in more than 1700 healthcare organizations in over 44 countries use Franklin to personalize cancer treatments to the patient’s genetic … Continue reading →

11 new projects have been granted a total of NIS 32 million in the 4th annual round of the Israel Precision Medicine Partnership (see here previously). They include AI for cancer and Crohn’s, discovery of new disease genes, and treatments … Continue reading →

Scientists at Israel’s Weizmann and Technion Institutes have found that each melanoma patient has a different profile of neo-antigens (mutated peptides) on their tumors. Doctors can then extract and grow the T-cells best suited to target the neo-antigens on both … Continue reading →

The breakthrough CAR-T personalized leukemia therapy devised by Professor Zelig Eshhar of Israel’s Weizmann Institute (see here) is now available in the UK.  The National Health Service will fund Kymriah – the CAR-T treatment commercialized by Novartis. https://www.telegraph.co.uk/news/2018/09/04/nhs-fund-game-changing-personalised-cancer-drug/

I wrote previously (10th Dec) about Israeli personalized cancer biotech Ayala and its partnership with Bristol-Myers Squibb. One of the results of this tie-up is AL101 – a new treatment for metastatic Adenoid Cystic Carcinoma (ACC), which could also treat … Continue reading →

Israel’s NovellusDx (see Jun 2016) has received a $900,000 BIRD Foundation award to identify and design personalized cancer therapies for the Delaware-based Gene Editing Institute. NovellusDx also won 1st prize in the international Quality Innovation Award competition. http://www.phillyisraelchamber.com/bird-u-s-israel-binational-industrial-rd-foundation-invest-900000-novellusdx-christiana-care-gene-editing-institute-collaboration/ http://www.novellusdx.com/news/novellusdx-receives-1st-prize-in-the-international-quality-innovation-award-competition/